Daklataswir (Daclatasvir)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Included in the formulation
  • Daklinsa®
    pills inwards 
    Bristol-Myers Squibb Company     USA
    • АТХ:

    J.05.A.X.14   Daklataswir

    Pharmacodynamics:

    It binds to the domain of protein NS5A, thereby inhibiting the replication of viral hepatitis C, prevents the assembly of virions and their escape from the cell.

    Pharmacokinetics:

    After oral administration, the gastrointestinal tract is rapidly absorbed. Absolute bioavailability is 67%. The maximum concentration in the blood plasma is achieved in 1-2 hours. The connection with plasma proteins is 99.5%.

    Metabolism in the liver.

    The half-life is 12-15 hours. Elimination with feces.

    Indications:

    It is used for the treatment of chronic hepatitis C. It is used as part of complex therapy in combination with asunaprevir with viral hepatitis with genotype 1b.

    ICD-10

    I.B15-B19.B18.2   Chronic viral hepatitis C

    Contraindications:

    Pregnancy and lactation, age under 18 years, individual intolerance.

    Carefully:

    Elderly (over 65 years of age), severe renal failure.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and during lactation, as well as for men during pregnancy partners.

    Dosing and Administration:

    Inside, 60 mg once a day for 24 weeks.

    The highest daily dose: 60 mg.

    The highest single dose: 60 mg.

    Side effects:

    Central and peripheral nervous system: faint.

    Circulatory system: peripheral edema.

    Hematopoietic system: anemia, lymphopenia, thrombocytopenia, and leukopenia.

    Respiratory system: shortness of breath.

    Digestive system: diarrheal phenomena, diarrhea.

    Endocrine system: hypothyroidism.

    Sense organs: rarely - retinopathy.

    Dermatological reactions: rash, photosensitivity reactions.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Rifampicin reduces the effectiveness of daklatasvir up to 90%.

    Ritonavir potentiates the action of daklatasvir.

    Simultaneous use with indinavir leads to hyperbilirubinemia.

    Reduces the effectiveness of saquinavir with simultaneous admission.

    Slows the metabolism of irinotecan, increasing its toxicity.

    Potentiates the action of lidocaine, amiodarone, quinidine, diltiazem.

    Strengthens the effect of warfarin, which can lead to bleeding.

    Absorption of the drug is significantly reduced with the use of antacid agents (due to a decrease in the acidity of gastric juice).

    Proton pump inhibitors and histamine blockers H2-receptors reduce the concentration of daklatasvira in blood plasma, reducing the effectiveness of the drug.

    Reduces the effectiveness of hormonal contraceptives containing estradiol.

    Special instructions:

    If necessary, the appointment with nifedipine, verapamil, felodipine, nicardipine should titrate the dose of calcium channel blockers under the control of ECG.

    Instructions
    Up